Abstracts tagged "major histocompatibility complex (MHC) and spondylarthritis"

Abstract Number: 2082 • 2018 ACR/ARHP Annual Meeting
ERAP1 Deficiency Partially Relieves HLA-B27-Induced ER Stress and IL-23 Expression, but Does Not Restore Dendritic Cell Function in Experimental Spondyloarthritis
Tri Tran¹, Vance Holt², Tejpal Gill¹, Joshua R. Bennett², Joel Taurog³ and Robert Colbert⁴, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Dept Int Med-Rheum Dis Div, University of Texas Southwestern Medical Center, Dallas, TX, ⁴National Institute of Arthritis and Musculuskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Preliminary results suggest that endoplasmic reticulum (ER) aminopeptidase 1 (ERAP1) deficiency partially protects HLA-B27/human b2m transgenic (B27-Tg) rats from spondyloarthritis (SpA) as evidenced by…
Abstract Number: 2699 • 2016 ACR/ARHP Annual Meeting
Spa-Associated HLA-B*27 Subtypes Accumulate More in Endoplasmic Reticulum (ER) Compartment and in Association with β2-Microglobulin (β2m) Than Non-Associated HLA-B Alleles
Nadège Jah¹, Gilles Chiocchia², Maxime A. Breban³ and Claudine Andre¹, ¹Infection and inflammation, INSERM UMR1173, Montigny-le-Bretonneux, France, ²Infection and Inflammation, INSERM-U1173, University of Versailles Saint-Quentin-en-Yvelines, France, Montigny-le-Bretonneux, France, ³Rheumatology, Ambroise Paré Hospital (AP-HP), Versailles Saint Quentin en Yvelines University, INSERM UMR1173, Boulogne-Billancourt, France
Background/Purpose: Mechanisms underlying the striking association of SpA with the MHC class I molecule HLA-B27 remain poorly understood. SpA-like disease develops spontaneously in B*2705 transgenic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].